Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

NCT01602406 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced HER2-positive Breast Cancer or Gastric Cancer

Interventions

DRUG: LJM716
DRUG: Trastuzumab

Sponsor

Novartis Pharmaceuticals